- Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
- Ligand Provides Highlights from its Investor and Analyst Day Event
- Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
- Ligand to Hold Investor and Analyst Day on December 13
- OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights
As of last trade
Ligand Pharmaceuticals Inc (LGND:NMQ) traded at 71.92, -14.33% below its 52-week high of 83.95, set on Nov 14, 2022.
45.25Jun 14 202283.95Nov 14 2022
Markit short selling activity
|Market cap||1.21bn USD|
|EPS (TTM)||-1.27 |
Data delayed at least 15 minutes, as of Feb 06 2023 20:06 GMT.